EC approves Truvada for PrEP

The European Commission approved a label expansion for HIV therapy Truvada emtricitabine/tenofovir disoproxil fumarate from Gilead Sciences Inc. (NASDAQ:GILD) to include pre-exposure prophylaxis. Truvada is approved for use in combination with safer sex practices for PrEP to reduce the risk of sexually acquired HIV-1 in adults at high risk.

FDA approved Truvada for PrEP in 2012. The HIV drug is also approved for the indication in Australia, Kenya, Peru and South Africa. Truvada is a fixed-dose combination of the nucleoside analog reverse transcriptase inhibitor (NRTI) emtricitabine and the nucleotide reverse transcriptase inhibitor tenofovir. ...